Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 670-674

  Ghobrial, Irene M ^a   Xie, Wanling ^a   Padmanabhan, Swaminathan ^b   Badros, Ashraf ^c   Rourke, Meghan ^a   Leduc, Renee ^a   Chuma, Stacey ^a   Kunsman, Janet ^a   Warren, Diane ^a   Poon, Tiffany ^a   Harris, Brianna ^a   Sam, Amy ^a   Anderson, Kenneth C ^a   Richardson, Paul G ^a   Treon, Steven P ^a   Weller, Edie ^a   Matous, Jeffrey ^d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d Rocky Mountain Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; RITUXIMAB;

ADULT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; TIME; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; TIME FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 77956485113     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21788     Document Type: Article

References (22)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 2000;18:214-226. (Pubitemid 30036355)
2. Ghobrial IM, Witzig TE. Waldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5:239-247.
3. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:1564-1577.
4. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-115.
5. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003;4:679-685.
6. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 2009;113(18):4163-4170.
7. Ghobrial I, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: An Eastern Cooperative Oncology Group Study. Cancer 2004;101:2593-2598.
8. Treon S, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481-1483. (Pubitemid 39409737)
9. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007;26:3629-3636. (Pubitemid 46842700)
10. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia. Blood 2008;111(9):4752-4763.
11. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia. Blood 2008;111(10):5068-5077.
12. Gertz MA, Anagnostopoulos A, Anderson K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:121-126.
13. Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380-383.
14. Treon SP, Morel P, Leblond V, et al. Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:215-216. (Pubitemid 40614228)
15. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132-138. (Pubitemid 40124490)
16. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993;95:49-52.
17. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009;114(12):2375-2385.
18. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2008;27(1):120-126.
19. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250-255.
20. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom Macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27(23):3830-3835.
21. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. Clin Cancer Res 2007;13:3320-3325.
22. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's Macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(12):1570-1575.